Cumberland Pharmaceuticals, Inc. has acquired Vaprisol from Astellas Pharma US, Inc. Vaprisol is one of two branded prescription products indicated for the treatment of hyponatremia, an electrolyte disturbance associated with congestive heart failure, liver failure, kidney failure and pneumonia. The product was developed and registered by Astellas and was launched in 2006. 
 
Cumberland will assume full responsibility for marketing, distribution and manufacture. Cumberland will promote Vaprisol in the U.S. through its hospital sales force, which also features its Caldolor and Acetadote brands.
 
“We believe Vaprisol is an excellent strategic fit with our focus on hospital acute care,” said A.J. Kazimi, chief executive officer of Cumberland Pharmaceuticals. “Our immediate plan for Vaprisol is to ensure a smooth transition of the product supply and medical support to current users of the brand. We will then launch our hospital promotion support and are very optimistic about the opportunity that Vaprisol will offer Cumberland.”